- Home
- CANF vs PD Comparison
CANF vs PD Comparison
Compare CANF & PD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- PD
- Stock Information
- Founded
- CANF 1994
- PD 2009
- Country
- CANF Israel
- PD United States
- Employees
- CANF N/A
- PD N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- PD Computer Software: Prepackaged Software
- Sector
- CANF Health Care
- PD Technology
- Exchange
- CANF Nasdaq
- PD Nasdaq
- Market Cap
- CANF 7.9M
- PD 1.4B
- IPO Year
- CANF N/A
- PD 2019
- Fundamental
- Price
- CANF $1.13
- PD $15.76
- Analyst Decision
- CANF Strong Buy
- PD Buy
- Analyst Count
- CANF 2
- PD 11
- Target Price
- CANF $14.00
- PD $20.55
- AVG Volume (30 Days)
- CANF 423.1K
- PD 1.3M
- Earning Date
- CANF 05-06-2025
- PD 05-29-2025
- Dividend Yield
- CANF N/A
- PD N/A
- EPS Growth
- CANF N/A
- PD N/A
- EPS
- CANF N/A
- PD N/A
- Revenue
- CANF $674,000.00
- PD $467,499,000.00
- Revenue This Year
- CANF $461.72
- PD $10.99
- Revenue Next Year
- CANF N/A
- PD $9.23
- P/E Ratio
- CANF N/A
- PD N/A
- Revenue Growth
- CANF N/A
- PD 8.54
- 52 Week Low
- CANF $1.22
- PD $14.30
- 52 Week High
- CANF $4.69
- PD $23.12
- Technical
- Relative Strength Index (RSI)
- CANF 35.40
- PD 45.64
- Support Level
- CANF $1.14
- PD $14.30
- Resistance Level
- CANF $1.27
- PD $15.94
- Average True Range (ATR)
- CANF 0.12
- PD 0.90
- MACD
- CANF -0.02
- PD 0.05
- Stochastic Oscillator
- CANF 0.00
- PD 61.68
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About PD PagerDuty Inc.
PagerDuty Inc is a digital operations management platform that manages urgent and mission-critical work for a modern, digital business. Its PagerDuty Operations Cloud combines artificial intelligence (AI) operations (AIOps), automation, customer service operations, and incident management with a generative AI assistant to create a flexible, resilient, and scalable platform to protect revenue and improve customer experience, improve operational efficiency, and mitigate the risk of operational failures. The company generates revenue predominantly from cloud-hosted software subscription fees and term-license software subscription fees. Geographically, the firm derives a majority of its revenue from the United States and the rest from International markets.